Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7652W HIGH $4.68
Volume
274.88 K
Value Traded
201.07 K
Short % Float
4.81%
-13.55%Week
-53.82%1 Month
-76.51%3 Month
-63.39%6 Month
-75.85%5 Year
-76.35%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.39 M
EPS (TTM)
-1.46
P/E Ratio
-
Ent. Value
3.03 M
Total Shares
12.78 M
Float Shares
11.61 M
Insiders
22.23%
Institutions
17.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
LTRN Catalyst Timeline
Dated clinical, regulatory and corporate events for Lantern Pharma Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lantern Pharma Inc.
291Total events
16Upcoming
38Tier-1 (high impact)
2019 to 2042Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Concurrent private placement of unregistered warrants for up to 3,669,725 shares at $1.09 exercise price
▲Ethics Committee ApprovalLP-300Trial
Lead Taiwan site received local IRB approval for Part 2 of HARMONIC™ trial
Never-Smoker, EGFR-Mutant NSCLCsource ↗
▲Patent GrantedLP-284IP / Competition
USPTO issues Notice of Allowance for LP-284 method-of-treatment patent application 18/500,032
mantle cell lymphoma and double-hit lymphomasource ↗
◆Timing GuidancePresentation
Dedicated OMAI informational call planned for mid-September 2026
▲Trial Authorization (CTA / IND)LP-300Ex-US Regulatory
Taiwan FDA approved amended protocol for Part 2 of Phase 2 HARMONIC™ trial of LP-300
Never-Smoker, EGFR-Mutant NSCLCsource ↗
◆Timing GuidancePresentation
Conference call and webcast scheduled for Friday, August 14, 2026 at 9:00 a.m. ET
▲Partnership / LicenseCorporate
Lantern Pharma executes commercial licensing agreements with Open-Medicine AI
▲Partnership / LicenseCorporate
Open Medicine AI established as separate company with executed commercial licensing agreements
▲EMA ValidationLP-184Ex-US Regulatory
EMA clearance of investigator-initiated Phase 1b/2 trial of LP-184 in advanced bladder cancer
advanced/recurrent bladder cancersource ↗
▲Other Regulator MilestoneLP-184Ex-US Regulatory
EMA clears investigator-initiated Phase 1b/2 trial of LP-184 in advanced bladder cancer
advanced urothelial carcinoma (bladder cancer)source ↗
▲Patent GrantedLP-184IP / Competition
USPTO Notice of Allowance for patent covering biomarker-guided treatment with LP-184
solid tumor cancers (ovarian, primary liver, kidney, thyroid)source ↗
▲Trial CompletionLP-184Trial
Completed 63-patient Phase 1a trial of LP-184
recurrent or refractory advanced solid tumorssource ↗
▲Trial Authorization (CTA / IND)LP-184Ex-US Regulatory
EMA cleared investigator-initiated Phase 1b/2 trial of LP-184 (zirdafulven) in biomarker-selected bladder cancer
advanced bladder cancersource ↗
▲Product LaunchZetaOmicsPost-Market
ZetaOmics computational biology module released to early-access users
●Quarterly UpdateCorporate
Lantern Pharma reports Q2 2026 financial results with cash of approximately $7.4 million as of June 30, 2026
◆Oral PresentationLP-300Presentation
Presentation of HARMONIC trial data at ASCO 2026
EGFR Exon 21 L858R-mutant non-small cell lung cancersource ↗
▲Protocol AmendmentLP-300Trial
FDA-cleared protocol amendment extending LP-300 dosing from six to eight cycles
EGFR Exon 21 L858R-mutant non-small cell lung cancersource ↗
◆Enrollment UpdateLP-300Trial
Enrollment concentrated on L858R subgroup; additional data expected as cohort matures
EGFR Exon 21 L858R-mutant non-small cell lung cancersource ↗
▲Topline ReadoutLP-300Clinical Data
Emerging HARMONIC data show deepened PFS benefit with treatment duration in L858R patients
EGFR exon 21 L858R lung cancersource ↗
●Oral PresentationLP-300Presentation
Rodman & Renshaw fireside chat with Dr. Joseph Treat on never-smoker lung cancer
never-smoker NSCLC adenocarcinomasource ↗
▲Type C MeetingLP-300FDA Meeting
FDA Type C meeting request successful; no objections to proposed protocol amendments
never-smoker NSCLC adenocarcinomasource ↗
▲Protocol AmendmentLP-300Trial
Protocol amendment to focus enrollment on EGFR exon 21 L858R, transition to single-arm, extend LP-300 dosing to 8 cycles
never-smoker NSCLC adenocarcinomasource ↗
▼Equity OfferingCorporate
Registered direct offering closed raising approximately $4.4 million gross proceeds
▲Type C MeetingLP-300FDA Meeting
Successful Type C meeting outcome with FDA for HARMONIC trial protocol amendments
non-small cell lung cancer (NSCLC) adenocarcinoma in never-smokerssource ↗
▲FDA Feedback ReceivedLP-300FDA Meeting
Successful Type C meeting outcome for LP-300 HARMONIC trial
non-small cell lung cancer (NSCLC) adenocarcinoma in never-smokerssource ↗
●Pipeline PrioritizationCorporate
Strategic plan to create independent entity for withZeta.ai
▲Protocol AmendmentLP-300Trial
FDA reviewed Phase 2 protocol amendments with no objections; enrollment focused on L858R, treatment extended to eight cycles, single-arm design
EGFR exon 21 L858R lung cancersource ↗
▲Topline ReadoutLP-300Clinical Data
Emerging data shows 8.3-month median PFS in EGFR L858R lung cancer after targeted therapy failure
EGFR L858R lung cancersource ↗
▲Full ResultsLP-300Clinical Data
Preliminary HARMONIC data cutoff (n=31) showing safety and efficacy data
never-smoker NSCLC adenocarcinomasource ↗
▲Product LaunchwithZeta.aiPost-Market
withZeta.ai platform launched for rare cancers
rare and aggressive cancerssource ↗
●Enrollment UpdateLP-300Trial
HARMONIC trial continues patient enrollment in US, Japan, and Taiwan
never-smoker NSCLC adenocarcinomasource ↗
▲IND ClearanceSTAR-001IND
FDA clearance of IND for STAR-001 Phase 1 pediatric CNS cancer trial
pediatric CNS malignancies (ATRT, DIPG, GBM, medulloblastoma, ependymoma)source ↗
◆Oral PresentationPresentation
Lantern Pharma CEO to present at 7th Glioblastoma Drug Development Summit
glioblastoma, ATRTsource ↗
▲Orphan Drug DesignationLP-284Designation
FDA grants Orphan Drug Designation to LP-284 for soft tissue sarcomas
soft tissue sarcomassource ↗
▲IND ClearanceSTAR-001IND
FDA cleared IND for STAR-001 pediatric CNS cancer trial
pediatric CNS cancer (ATRT and other rare pediatric cancers)source ↗
▲Orphan Drug DesignationLP-284Designation
FDA Orphan Drug Designation for LP-284 in soft tissue sarcomas
soft tissue sarcomassource ↗
▲Platform ValidationPreclinical
Initiation of AI Center of Excellence in India to industrialize RADR and withZeta.ai
●Manufacturing MilestoneCMC / Inspection
Lantern establishes AI Center of Excellence in Bengaluru, India
▲Product LaunchPost-Market
withZeta.ai multi-agentic AI co-scientist platform introduced and in beta testing with over 25 organizations
◆Timing GuidancePresentation
Large-scale rollout of multi-agentic system for rare cancers planned to be made public in December
Past FDA Catalysts and PDUFA Decisions
How LTRN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | LP-184 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$19M
Pipeline Value
Fair Value
Valuation Signal
5
Drugs Scored
1.9x
rNPV / MCap
Top 42%
Micro Cap(rank 278 of 660)
Percentile Rank
Lantern Pharma Inc. faces pipeline headwinds (39/100), with $2.3B risk-adjusted pipeline value, led by Tavocept in combination with cisplatin and either docetaxel or paclitaxel in Non-small Cell Lung Cancer (Phase 3), across $52B in total addressable markets, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tavocept in combination with cisplatin and either docetaxel or paclitaxel Small moleculeCompletedNCT00966914 | Non-small Cell Lung Cancer | Phase 3 | COMPLETED | 540 | Jun 1, 2013 |
Clinical Trial Results
Readouts, endpoints and source filings for every LTRN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LP-300 | EGFR Exon 21 L858R-mutant non-small cell lung cancer (NSCLC) | Phase 2 | 2026-06-02 | median PFS: 8.9 months; overall L858R cohort median PFS: 8.4 months; hazard ratio: 0.37; clinical benefit rate: 77%; durable responses: beyond two yearsRead More | Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Schalop Lee TroyDirector | Buy | 48,544 48,544 held | $2.06 | 05/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LTRN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LTRN for Q2 2026. | ||||
LTRN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LTRN ranks across every disease it competes in
Competitive Position is a premium feature
See how LTRN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLTRN News
LTRN▼ -8.8%on this news
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
Lantern Pharma has announced its participation in the ThinkEquity Conference scheduled for October 15th, 2026, in New York City. This event presents an opportunity for the company to showcase its developments and engage with potential investors. The conference is expected to highlight Lantern's ongoing projects and future plans.
Read more →LTRN▼ -0.1%today
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Lantern Pharma has received necessary regulatory and IRB approvals in Taiwan to proceed with Part 2 of its Phase 2 HARMONIC™ trial for LP-300, targeting never-smoker, EGFR-mutant NSCLC patients. The Taiwan Food and Drug Administration approved the amended protocol in September, with local IRB approval following shortly after. This advancement marks a significant step in the trial's progression.
Read more →LTRNLantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
Lantern Pharma Inc. has successfully closed a registered direct offering, raising up to $8 million. This funding is expected to support the company's ongoing growth initiatives and enhance its operational capabilities. The announcement highlights the company's strategic financial moves in the biopharma sector.
Read more →LTRNLantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
Lantern Pharma Inc. has announced a registered direct offering of up to $8 million, selling 3,669,725 shares at a price of $1.09 each. This funding aims to support the company's development of precision oncology therapies using artificial intelligence and genomic data. The move reflects Lantern's commitment to advancing its clinical-stage initiatives.
Read more →LTRNOpen-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
Lantern Pharma is set to present its insights on the Agentic AI drug development market today at 12:30 PM ET. The presentation will cover user needs, development roadmap, platform economics, and benchmarks. This initiative highlights the company's commitment to leveraging AI in drug development.
Read more →LTRN▼ -9.3%on this newsshared move
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
Lantern Pharma has announced the receipt of a Notice of Allowance from the USPTO for its patent application concerning LP-1284, a drug candidate aimed at treating aggressive B-cell lymphomas, including mantle cell lymphoma. This development marks a significant step in the company's efforts to advance its oncology drug discovery and development initiatives.
Read more →LTRN▼ -11.4%on this news· ran to -30% by day 3shared move
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
Lantern Pharma Inc. will host a live webinar on September 23, 2026, to discuss its Open-Medicine AI platform. The presentation will cover the business model, development roadmap, and value proposition of this multi-agentic AI system designed for therapeutic development. This initiative highlights the company's focus on precision oncology.
Read more →LTRNLantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Lantern Pharma has released its financial results for the second quarter of 2026, alongside a business update. The report highlights the company's performance and strategic direction. Further details on financial metrics and future plans were not provided in the article.
Read more →LTRNLantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
Lantern Pharma has announced that it will report its operating and financial results for the second quarter of 2026. The report is scheduled for August 14th, 2026, at 9:00 a.m. ET. This update is part of the company's regular financial reporting process.
Read more →LTRNLantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
Lantern Pharma has announced the establishment of Open Medicine AI as a separate company. This new entity aims to commercialize and enhance its Multi-Agent AI Co-Scientist Platform, which is designed to transform the field of medicine. The initiative reflects Lantern Pharma's commitment to innovation in healthcare technology.
Read more →LTRN▼ -6.8%on this news
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
Lantern Pharma has received clearance from the European Medicines Agency (EMA) to advance its Phase 1b/2 clinical trial for LP-184, also known as Zirdafulven, targeting biomarker-selected advanced bladder cancer. This development highlights the company's commitment to developing innovative therapies for this challenging condition. The trial aims to assess the efficacy and safety of LP-184 in this specific patient population.
Read more →LTRNLantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
Lantern Pharma has received a Notice of Allowance from the USPTO for its patent application concerning biomarker-guided treatment methods for solid tumor cancers. This patent will enhance the company's ability to develop targeted therapies using its AI and genomic data capabilities. The allowed claims specifically focus on methods for selecting and treating patients with various solid tumors.
Read more →LTRN▼ -13.2%on this news
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
Lantern Pharma has launched ZetaOmics, an autonomous computational biology module designed to enhance bioinformatics and multi-omic analysis for all cancer types. This innovative tool is particularly focused on addressing the needs of rare and pediatric cancers. The introduction of ZetaOmics marks a significant advancement in the company's AI-driven precision oncology efforts.
Read more →LTRNLantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Lantern Pharma reported promising data from its Phase 2 HARMONIC™ trial for LP-300 in patients with EGFR Exon 21 L858R-mutant NSCLC. The trial indicates that progression-free survival improves with longer treatment durations, with a median PFS of 8.9 months for patients receiving up to six cycles. The safety profile remains favorable, supporting an extension of treatment cycles from six to eight.
Read more →LTRNLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Lantern Pharma has announced a successful outcome from its FDA Type C meeting regarding the HARMONIC™ Phase 2 trial of LP-300. This trial specifically targets never-smokers diagnosed with non-small cell lung cancer (NSCLC). The positive feedback from the FDA is a significant step forward for the company's development plans.
Read more →LTRNLantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
Lantern Pharma reported a 27% reduction in net loss year-over-year for Q1 2026 and emphasized capital-efficient operations. The company advanced multiple clinical programs, including successful FDA interactions, while simultaneously launching its AI platform, withZeta.ai. Financially, Lantern strengthened its balance sheet with $9.25 million in financing and plans to create a separate entity for its AI assets. The HARMONIC trial for LP-300 is ongoing, targeting specific patient populations in multiple countries and has shown promising early safety data.
Read more →LTRN▲ +24.7%on this newsshared move
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
Lantern Pharma Inc. announced a registered direct offering that could raise up to $9.25 million, which includes a $4.4 million upfront payment and potential additional funds through the exercise of warrants. Concurrently, the company plans to establish a separate business entity focused on its AI platform, aimed at enhancing its fundraising efforts. The closing of the offering is expected around May 14, 2026, pending customary conditions. Investors have expressed optimism regarding the company's AI capabilities, though there are risks related to the exercise of warrants and the success of product development.
Read more →LTRNLantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
Lantern Pharma Inc. will report its first quarter 2026 operating and financial results on May 15, 2026. The report will include financial results for the quarter ending March 31, 2026, along with updates on clinical trials and the development of the company's AI platforms. Lantern Pharma focuses on precision oncology therapies using AI and machine learning.
Read more →LTRNLantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™
Lantern Pharma has announced a new development roadmap for its withZeta.ai platform, which is designed to enhance oncology research and drug discovery through AI. The roadmap includes the introduction of two major components: ZetaSwarm™, a multi-agent swarm intelligence layer, and ZetaOmics™, a computational biology toolkit. These advancements aim to improve the efficiency and effectiveness of drug discovery processes.
Read more →LTRN▼ -11.6%on this news
Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally
Lantern Pharma has announced the evolution of its predictBBB.ai platform into a Large Quantitative Model (LQM), providing real-time molecular intelligence accessible via a web interface. This advancement enables pharmaceutical scientists and medicinal chemists to enhance their drug development processes. The LQM aims to improve precision oncology efforts globally.
Read more →About Lantern Pharma Inc.
Headquarters1920 MCKINNEY AVENUE, DALLAS, TX, 75201
BIOPHARMAWATCH ELITE PLUS
Trade the next LTRN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime